share_log

HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $8 Price Target

Benzinga ·  Jun 27 00:22

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment